Roche bulks up in inflammation with €380m Inflazome acquisit...

Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech Inflazome a couple of years after snapping up

IL-6 hypothesis looking shaky as Kevzara fails COVID-19 tria...

Hopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results from the first large-scale trial of Sanofi

FDA clears emergency use of Roche test for COVID-19 'cytokin...

Innovating in inflammation and immunology

For World Inflammatory Bowel Disease day we spoke to Pfizer’s Matt Shaulis, president of international developed markets for inflammation and immunology, to hear how the company hopes to ha

Verona says FDA backs plan to take COPD drug into phase 3

More than two years after first saying it would take its lead drug into a pivotal trial, Verona Pharma looks like it may finally follow through on that promise.

Blockbusters in waiting: drug launches to watch in 2020